White House Accelerates Psychedelic Therapies to Tackle Serious Mental Illness

The White House issues a policy order to speed up research, review, and potential approval of psychedelic medicines (including ibogaine) for serious mental illnesses, expanding access through Right to Try pathways, prioritizing FDA reviews for Breakthrough Therapy-designated drugs, funding federal-state collaboration, and boosting data sharing with the VA and private sector, while pursuing timely rescheduling of Schedule I substances after Phase 3 trials — all within existing laws and funding constraints, with a focus on veterans and reducing suicidality.